Plus Therapeutics, Inc. (PSTV)
NASDAQ: PSTV · Real-Time Price · USD
1.160
-0.360 (-23.68%)
At close: Mar 28, 2025, 4:00 PM
1.100
-0.060 (-5.17%)
After-hours: Mar 28, 2025, 7:59 PM EDT
Plus Therapeutics Revenue
In the year 2024, Plus Therapeutics had annual revenue of $5.82M with 18.54% growth. Plus Therapeutics had revenue of $1.41M in the quarter ending December 31, 2024, with 7.54% growth.
Revenue (ttm)
$5.82M
Revenue Growth
+18.54%
P/S Ratio
1.32
Revenue / Employee
$291,200
Employees
20
Market Cap
39.37M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
PSTV News
- 3 days ago - Plus Therapeutics, Inc. (PSTV) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 3 days ago - Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - GlobeNewsWire
- 10 days ago - Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate - GlobeNewsWire
- 11 days ago - Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025 - GlobeNewsWire
- 19 days ago - D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement - Accesswire
- 20 days ago - Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement - GlobeNewsWire
- 23 days ago - Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma - GlobeNewsWire
- 24 days ago - Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer - GlobeNewsWire